Pfizer’s selection of the HDI/PulseWave™ CR-2000 is another important milestone in the acceptance of this cutting edge, non-invasive technology by clinical researchers worldwide. According to Dr. Jay N. Cohn, Professor of Medicine in the Cardiovascular Division at the University of Minnesota and Chairman of the Company’s Scientific and Clinical Advisory Board, "Large and small arterial elasticity as measured by the HDI/PulseWave™ CR-2000 provides data to pharmaceutical researchers that is unavailable by any other non-invasive technology."

Greg H. Guettler, President of HDI, said, "We are very pleased to have entered into this new relationship with Pfizer, one of the world’s leading pharmaceutical companies. This relationship is further demonstration of HDI’s stated mission to become the standard for the non-invasive testing of the arterial elasticity of clinical research subjects."

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not predictions of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2000 Annual Report on Form 10-KSB under the caption "Risk Factors", as well as others not now anticipated.

Hypertension Diagnostics, HDI/PulseWave™ and CVProfilor^® are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Contact: Greg H. Guettler, President